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Abstract
Objective: Post-operative cognitive decline is a surgical
complication involving chronic impairments in different
cognitive domains. Although the exact mechanisms
behind postoperative cognitive decline are still unknown,
there is increasing evidence for a key role of neuro-
inflammation. This meta-analysis aims to investigate the
efficacy of anti-inflammatory treatment on postoperative
cognitive decline.
Participants and Methods: An electronic search was
performed using PubMed, Psychinfo, EmBase, Cochrane
Database of Systematic Reviews and clinicaltrial.gov (until
November 2019). No year or language restrictions were
applied. Only randomized, double-blind, placebo-
controlled studies that investigated clinical outcome in
adult patients who underwent surgery under general
anaesthesia (except brain surgery) were included. The
search yielded 574 papers, of which nineteen fulfilled the
inclusion criteria.
Results: The current meta-analysis found a significant
effect of different anti-inflammatory agents on the
incidence of POCD (OR=0.67, p=0.010). Administration of
COX-2 inhibitors (OR=0.31, p<0.0001), ketamine (OR=0.44,
p=0.38) and lidocaine (OR=0.79, p=0.33) showed better
results than placebo in a meta-analysis of at least two
studies. Erythromycin (OR=0.14, p=0.006), erythropoietin
(OR=0.15, p=0.07) and dexmedetomidine (OR=0.58,
p=0.03) were significant in single studies. No beneficial
effects on cognition were found for magnesium, 17β-
estradiol, dexamethasone and melatonin.
Conclusion: The results of this meta-analysis provide
evidence for a potential efficacy of anti-inflammatory
agents on POCD, but further research is necessary to
determine which agents are most appropriate for clinical
application.
Keywords: Neuroinflammation; Postoperative cognitive
dysfunction (POCD) ; Anti-inflammatory agents; Meta-
analysis
Introduction
With an aging population and advanced surgical techniques,
more patients will undergo surgery at advanced age, with the
risk of postoperative cognitive decline (POCD) [1]. POCD is a
surgical complication involving chronic impairments in
different cognitive domains, including memory, attention,
learning, information processing and executive functions [2].
These impairments often become apparent in days to weeks
after surgery. POCD can have serious consequences as it
adversely affects independent living, quality of life and
mortality [3]. Risk factors for POCD include advanced age,
major surgery and pre-existing cognitive impairment [4].
POCD can be distinguished from postoperative delirium
(POD), which is defined as an acute fluctuating and transient
disturbance of perception and cognition that cannot be
attributed to a pre-existing neurocognitive disorder [5] and
usually occurs within the first three days after surgery [6].
POCD can best be detected with a set of neuropsychological
tests, applied before and after surgery. Usually, these are more
extensive tests than delirium screening tools [7].
Neuroinflammation
Although the exact mechanisms behind POCD are still
unknown, there is increasing evidence for a key role of neuro-
inflammation [8]. Tissue damage during surgery activates
damage-associated molecular pattern proteins, necessary for
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response [9], also affecting the brain and ultimately resulting
in microglia activation [10]. Microglia are the brain’s resident
immune cells. In response to extensive tissue damage and
subsequent immune activation, microglia can become
activated, resulting in reduced production of growth factors,
more extensive synaptic pruning [11] and increased
production of pro-inflammatory products (cytokines).
Cytokines, such as brain-derived neurotrophic factor (BDNF),
tumor necrosis factor alfa (TNFα), interleukin 1 (IL-1) and
interleukin 6 (IL-6), further activate the immune system,
having a detrimental effect on memory, neuroplasticity and
neurogenesis [12-14]. They may also negatively affect
neuronal functioning through the modulation of intraneuronal
pathways [15].
In particular BDNF and its intraneuronal pathway have been
implicated as mediators between neuro-inflammation and
cognitive impairment [16]. Hence, multiple processes may
cause cognitive impairment, including neuronal loss and
decreases in neurogenesis [17], synaptic plasticity [18] and
long-term potentiation [19]. A meta-analysis of clinical data
showed that elevated peripheral inflammatory markers are
indeed associated with POCD, with the strongest relationship
for IL-6 [20]. In POCD, the inflammatory response seems to be
derailed, with elevated peripheral inflammatory factors,
inducing lasting cognitive deficits [20]. As a consequence,
interventions to moderate the immune response during and
after surgery may help to rescue cognition.
Anti-inflammatory medication
Medical interventions that slow down or stop microglial
activation may consequently prevent or reverse cognitive
deterioration. Therefore, several studies have investigated the
effect of anti-inflammatory medication on POCD. Recent
studies on the effects of individual anti-inflammatory agents
on POCD have provided promising results [21-24]. However,
for a large part of these studies, POCD diagnosis was based on
only one cognitive screening instrument (Mini Mental State
Examination), which is not appropriate for a proper diagnosis
[7]. To the best of our knowledge this is the first meta-analysis
to provide an overview of the effects of different anti-
inflammatory agents on POCD that used a battery of
neuropsychological tests for POCD diagnosis. Consequently,
this overview may provide a rational for future clinical studies
and hospital strategies.
Research Methodology
This meta-analysis was performed in accordance with the
Preferred Reporting Items for Systematic Review and Meta-
Analyses (PRISMA) guidelines [25]. An electronic search was
performed using PubMed, Psychinfo, EmBase, Cochrane
Database of Systematic Reviews and clinicaltrial.gov. The basic
search terms that were used are: postoperative cognitive
dysfunction OR postoperative cognitive decline OR POCD AND
the specific pharmacological components. Besides the well-
known NSAIDs (aspirin, celecoxib, ibuprofen, diclofenac, and
naproxen), and corticosteroids (prednisone, prednisolone,
hydrocortisone, methylprednisolone, dexamethasone,
cortisone, triamcinolone, and betamethasone), many
pharmacological agents have some degree of anti-
inflammatory action. For some, this is their predominant
function, for others this is just a pleiotropic effect.
Therefore, we selected all agents that have some anti-
inflammatory aspects, as demonstrated in (rodent)
experimental settings, resulting in a very broad range,
including: davunetide, EPA and DHA fatty acids, estrogens
(including also selective estrogen receptor modulators),
specific antibiotics (e.g., minocycline), n-acetyl cysteine (NAC)
and transplantation adjuncts (tacrolimus, cyclosporine,
everolimus, serolimus, mycophenolate mofetil), cytostatics
(bexarotene, bone marrow irradiation/transplantation,
methotrexate, cyclophosphamide), melatonin, ketamine,
parecoxib, erythromycin, dexmedetomidine, piracetam,
statins, pregabalin, lidocaine, erythropoietin, propofol,
thiopental, xenon and magnesium. The search dates ranged
from the establishment of each database to November 2019.
Inclusion criteria
Studies are included based on the following criteria:
• Only randomized, double-blind, placebo-controlled studies
that investigated clinical outcome are included.
• Studies include postoperative patients of all ages.
• Studies include patients with surgery under general
anaesthesia, except brain surgery.
• Post-operative cognitive functioning is measured using a
battery of neuropsychological tests.
• Studies included report sufficient information to compute
common effect size statistics of change scores (i.e., means
and SDs, exact P-, t- or z-values).
Cross-over, preventive intervention and treatment studies
are also included. No year or language restrictions are applied.
Outcome measures
The primary outcome measure is the difference in incidence
of POCD between treatment group and control group. POCD
was measured as the post-operative change in scores on
neuropsychological tests compared to pre-operative
measurement. Different diagnostic criteria were used to define
POCD (Table 1). The criterion used for each study can be found
in Table 2.
Statistical analyses
The meta-analysis was conducted using Review Manager
Version 5.3 (Review Manager, 2014). The odds ratios (ORs)
with 95% confidence intervals (CIs) were used to express the
effect-size. The odds ratio for each study was calculated using
the available data provided in the paper. This included the
incidence of POCD per group and the sample sizes of the
treatment group and control group. A random effects model
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was applied because of functional differences between
included studies [26].
Table 1: Definitions of post-operative cognitive dysfunction.
Num
ber Criterion
1 A decline of 1 SD in at least 1 test
2 A decline of 1 SD in at least 2 tests
3 A decline of 1 SD in at least 1 domain (consisting of multiple tests)
4 A decline of 1 SD in at least 2 subtests (from different tests)
5 A decline of 2 SD in at least 1 test
6 A decline of 2 SD in at least 2 tests or the composite test score
7 A 20% reduction in 20% of tests
8
Reliable Change Index (RCI) equal to or less than -1.96 on at least
1 test
9
Reliable Change Index (RCI) equal to or less than -1.96 on at least
2 tests
To measure the degree of heterogeneity between studies, I2
was calculated. This measure describes the percentage of total
variation across studies that are caused by heterogeneity
rather than chance [27].
Values of I2 can range from 0% to 100%, whereby the
following interpretations for heterogeneity are suggested by
the Cochrane Collaboration: low (0-40%), moderate (30-60%),
substantial (50-90%) and high (75-100%) [25].
Meta-regression of categorical moderators was performed
when at least four studies were available [28]. Following this
rule, the effects of type of surgery (cardiac or non-cardiac) and
time of measurement (>1 month) were assessed using
StataVersion 15 (Statacorp., 2017). All results with a p-value
<0.05 were considered significant.
Results
The search yielded 574 papers, of which 133 remained after
removal of duplications and subsequent screening on title and
abstract. Full-text reading resulted in nineteen papers that
fulfilled the inclusion criteria (Figure 1). The current meta-
analysis included ten different anti-inflammatory agents and a
total of 2117 patients and 2097 healthy controls.
Characteristics of the included studies are shown in Table 2.
Some studies included measurements at different time points.
In this case only the first measurement was selected to avoid
practice effects.
Table 2: Characteristics of the included studies.
Author
(year) Type of surgery
Anti-
inflammatory




(1999) Cardiac surgery Lidocaine
1 mg/kg bolus + 240 mg/h (1 h), 120 mg/h
(2 h) and 60 mg/h (2 days) 10 Weeks 26 1
Wang (2002) Cardiac surgery Lidocaine
1.5 mg/kg bolus + 4 mg/min intraoperative
infusion 9 Days 43 4
Nagels
(2004) Cardiac surgery (S+) ketamine
2.5 mg/kg bolus + 125 μg/kg/min
intraoperative infusion 10 Weeks 50 2
Hogue
(2007) Cardiac surgery 17β-estradiol
0.01 ng/kg/min from 1 day preoperatively (6
days) 4-6 Weeks 86 2
Haljan
(2009) Cardiac surgery Erythropoietin
375, 750 or 1500 U/kg bolus 1 day before,
during and 1 day after surgery 2 Months 24 7
Hudetz
(2009) Cardiac surgery Ketamine 0.5 mg/kg bolus intraoperative 1 Week 26 6
Mathew
(2009) Cardiac surgery Lidocaine 1 mg/kg bolus + infusion (2 days) 6 Weeks 88 3
Mitchell
(2009) Cardiac surgery Lidocaine
1 mg/kg bolus + 2 mg/min (2 h) and 1
mg/min (12 h) 10 Weeks 59 1
Mathew
(2013) Cardiac surgery Magnesium
50 mg/kg bolus + 50 mg/kg intraoperative












mastectomy Melatonin 6 mg bolus daily (3 months) 3 Months 27 6
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Ottens
(2014) Cardiac surgery Dexamethasone 1 mg/kg intraoperative bolus 1 Month 140 8
Lee (2015)
Orthopedic




40 mg bolus intraoperative and 12 h
postoperative 1 Week 60 2
Glumac
(2017) Cardiac surgery Dexamethasone 0.1 mg/kg bolus 10 h preoperative 6 Days 80 8
Thomaidou
(2017) Cardiac surgery Erythromycin
25 mg/kg bolus 12 h preoperative + 12 h




200 mg every 12 h for 7 days starting the





0.5 mg/kg bolus followed by 0.4 mg.kg.hr
infusion 1 Week 269 9
Klinger
(2019) Cardiac surgery Lidocaine
1 mg/kg bolus followed by a continuous
infusion 6 Weeks 211 3
Figure 2 shows the effect of different anti-inflammatory
agents on POCD. An odds ratio of 0.67 was found, indicating a
significant effect of anti-inflammatory agents on the incidence
of POCD (Z=2.59, p=0.010). Heterogeneity was substantial to
high (I2=71%). Using the arbitrary cut-off of a sample size of
less than 1000 patients for a lack of power, this meta-analysis
has sufficient power. Sub analyses on individual anti-
flammatory agents are presented below.
Erythromycin
Thomaidou et al. found an odds ratio of 0.14 for the effect
of erythromycin on POCD (Z=2.72, p=0.006) [29].
Erythropoietin
Haljan et al. investigated the effect of three doses of
recombinant human erythropoietin (rHuEpo) given the day
before, during, and the day after coronary artery bypass
grafting (CABG) surgery [30]. Two months after surgery, POCD
occurred in 8.3% of patients in the treatment group and in
38.0% of patients in the placebo group (OR=0.15, Z=1.82,
p=0.07).
COX-2 inhibitors
One week post-surgery, patients receiving COX-2 inhibitors
during total knee arthroplasty experienced significantly less
POCD than healthy controls (OR=0.31, Z=3.90, p<0.0001
[31,32]. There was no heterogeneity between studies (Figure
3).
Ketamine
The effect of ketamine on POCD was investigated in three
different studies showing inconsistent results with an odds
ratio of 0.44 (Z=0.88, p=0.38) [33-35]. Heterogeneity was
substantial to high (I2=77%) (Figure 4).
Dexmedetomidine
Intra-operative dexmedetomidine was found to reduce
POCD in elderly patients undergoing laparotomy (OR=0.58,
Z=2.22, p=0.03) [36].
Lidocaine
Five different studies measured the effect of lidocaine on
POCD after cardiac surgery, with an overall odds ratio of 0.79
(Z=0.98, p=0.33) [37-41]. Heterogeneity was moderate to
substantial (I2=55%) (Figure 5).
Magnesium
Mathew et al. found no effect of the administration of
magnesium on POCD six weeks after surgery (OR=0.99, Z=0.05,
p=0.96) [42].
17β-estradiol
Hogue et al. found no significant effect of 17β-estradiol on
POCD at four to six weeks postoperatively (OR=1.03, Z=0.08,
p=0.94) [43].
Dexamethasone
The effect of dexamethasone on POCD is investigated by
three studies (OR=1.05, Z=0.16, p=0.88), showing contrasting
results (Figure 6) [44-46]. Fang et al. administrated
dexamethasone at doses of 0.1 mg/kg (a) and 0.2 mg/kg (b)
[44]. The incidence of POCD was 22.3% in the placebo group,
20.6% in the low-dose dexamethasone group and 31.4% in the
high-dose dexamethasone group. Heterogeneity between the
studies was substantial to high (I2=79%).
Melatonin
Hansen et al. investigated the effect of melatonin on POCD.
However, there was only one patient with POCD at three
months post-operatively (OR=1.87, Z=0.38, p=0.71) [47].
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Effect of moderators
Meta-regression analysis showed that type of surgery
(p=0.863) and time of measurement (p=0.201) were
insignificant predictors for the effect of anti-inflammatory
medication on POCD.
Figure 1: Preferred reporting items for systematic reviews and meta-analyses (2009) flow diagram.
Discussion
The current meta-analysis provides a quantitative
systematic overview of literature regarding the efficacy of
agents with anti-inflammatory properties on the incidence of
POCD. A total of nineteen randomized controlled trials, using
ten different anti-inflammatory agents were included. Overall,
the administration of different anti-inflammatory agents was
found to significantly reduce the incidence of POCD in
patients. Administration of COX-2 inhibitors, ketamine and
lidocaine showed better results than placebo in a meta-
analysis of at least two studies. Erythromycin, recombinant
human erythropoietin (rHuEpo) and dexmedetomidine were
significant in single studies. No beneficial effects were found
for magnesium, 17β-estradiol, dexamethasone and melatonin.
Anti-inflammatory agents that showed
replicated significant result
COX-2 inhibitors, ketamine and lidocaine were found to be
effective anti-inflammatory agents in reducing incidence of
POCD. COX inhibitors reduce the activation of microglia and
subsequent neuroinflammation [48]. This meta-analysis
showed that cognitive performance one week post-surgery
was significantly better in the COX-2 inhibitor group compared
to controls [31-32].
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Ketamine is a common anesthetic agent with a range of
pharmacological effects that are potentially neuroprotective
[49]. It prevents the extension of local inflammation without
blunting the local process and delaying inflammatory
resolution [50]. In the current meta-analysis, ketamine
reduced POCD incidence in cardiac surgery, but this finding
could not be replicated in non-cardiac surgery [33-35].
Figure 2: Meta-analysis of the effect of different anti-inflammatory agents on POCD.
Figure 3: Meta-analysis of the effect of COX-2 inhibitors on POCD.
Figure 4: Meta-analysis of the effect of ketamine on POCD.
Lidocaine is a commonly used local anaesthetic and
antiarrhythmic drug targeting specific voltage-gated sodium
channels associated with neuropathic and inflammatory pain.
Due to its capacity to suppress pain, it has been proposed that
lidocaine may likewise reduce inflammatory responses [51].
Five studies measured the effect of different doses of lidocaine
on POCD, showing an overall cognitive improvement across
studies [37-41].
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Effective anti-inflammatory agents in single
studies
Other anti-inflammatory agents that may be effective are
erythromycin, recombinant human erythropoietin (rHuEpo)
and dexmedetomidine, of which administration resulted in a
significant reduction of POCD in single studies. Macrolide
antibiotics, such as erythromycin, are popular due to their
spectrum of activity and their relative safety [52]. The effects
of macrolides are not restricted to antibacterial properties, but
also involve modulation of a variety of inflammatory processes
[53]. Thomaidou et al. administrated a 25 mg/kg bolus of
erythromycin twelve hours before and twelve hours after
cardiac surgery and found a lower incidence of POCD at three
months post-surgery [29].
Figure 5: Meta-analysis of the effect of lidocaine on POCD.
Figure 6: Meta-analysis of the effect of dexamethasone on POCD.
Erythropoietin (EPO) directly affects cells of the nervous
system, which makes it an attractive candidate drug for
neuroprotection [54]. RHuEpo can attenuate the production of
proinflammatory cytokines and reduce the influx of
inflammatory cells into the damaged region [55]. Haljan et al.
demonstrated the feasibility and safety of rHuEpo as a
neuroprotective agent [30].
Dexmedetomidine is an α2 receptor agonist, used as a
sedative agent with analgesic properties [56]. A number of
mechanisms of dexmedetomidine have been presumed,
including the modulation of cytokine production, inhibition of
apoptosis and interactions between pain and immune factors
such as proinflammatory cytokines [57]. Cheng et al. found a
lower incidence of POCD in elderly patients undergoing
laparotomy after the intra-operative administration of
dexmedetomidine [36].
Other anti-inflammatory agents
Four of the investigated agents were not found to be
effective in reducing the incidence of POCD: magnesium, 17β-
estradiol, dexamethasone and melatonin. Magnesium sulfate
is an anti-convulsant that possesses anti-inflammatory
capacity, as it can inhibit endotoxin-induced upregulation of
inflammatory molecules [58]. However, no effect of
magnesium on POCD was found [42].
Estrogens, especially 17β-estradiol, also have mild anti-
inflammatory properties. 17β-estradiol reduces TNF-α and
NO25 in addition to actions such as reducing anti-oxidative
stress, influencing dopaminergic neurotransmission and
controlling energy balance and glucose homeostasis [59]. A
potential explanation for the failure of 17β-estradiol to
decrease the incidence of POCD might be inappropriate dosing
or duration of 17β-estradiol administration. It is possible that
early benefits were masked by ongoing neurological injury that
may have occurred after the short period of treatment [43].
Corticosteroids such as dexamethasone are often used as
additional drugs in anaesthesia to alleviate side effects such as
pain, fatigue and vomiting [60,61]. Dexamethasone may also
suppress the inflammatory reaction in the postoperative
period through inhibition of inflammatory cells and
suppression of inflammatory mediators [62,63]. However, no
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effect of dexamethasone on POCD was found in this meta-
analysis [44-46].
Melatoninis a neurohormone and a broad-spectrum
antioxidant [64]. The antioxidant activity of melatonin includes
the production of reactive oxygen and activation of pro-
oxidant enzyme, processes that fight the onset and
progression of inflammation [65]. The results of Hansen et al.
were difficult to interpret because of the small sample size and
small number of people with POCD [47].
Difficulties in POCD research
There are three major methodological difficulties when
evaluating different studies on POCD. First, there is no
standardized internationally accepted definition of POCD and
diagnostic criteria are lacking [8]. The most stringent criterion
for the diagnosis of POCD is a decline of at least two standard
deviations in two cognitive domains or in a single composite
cognitive score [66,67]. A more liberal criterion was proposed,
being a decline of at least one standard deviation in any
cognitive domain tested or in a composite cognitive score
compared to pre-operative performances [68]. Secondly,
diagnosing POCD is only possible with neuropsychological
testing [66]. However, there is no consensus on which tests
and test measures to use [69]. According to Krenk and
Rasmussen, test batteries should focus on different cognitive
domains and their sensitivity should allow the diagnosis of
mild deficits [70]. Finally, there is no consensus regarding the
optimal timing of neuropsychological testing after surgery [35].
Limitations
In the current meta-analysis, nine different definitions for
POCD were used (Table 1). It is important to consider that the
probability of identifying POCD in a patient depends on the
number of test measures used for analysis, which was shown
in the ISPOCD normative population. A decline of one standard
deviation was found in only 0.6% of the elderly volunteers
when one test measure was considered. This proportion
increased to 29% with the use of five test measures. When all
32 test measures were considered, 93% of the volunteers
showed a decline of one standard deviation in at least one
subtest [66]. Thus, on the one hand it is important to use a
sensitive test battery including several cognitive domains. On
the other hand, the number of tests included in the statistical
analysis should be limited in order to avoid large variability and
capitalization on chance. As an alternative, the results of
different neuropsychological tests can be combined and
expressed in a composite score. However, in doing so,
information on specific cognitive functions is lost. In trying to
deal with these issues, the current study compared incidences
of POCD by any used definition instead of using group means.
The disadvantage of this method is that a larger number of
patients needs to be included to achieve sufficient statistical
power [66]. In this study, the sub-analyses were seriously
underpowered.
In addition, the substantial inconsistency between studies
made it necessary to use random effect models that produced
wider confidence intervals. Differences exist in type of surgery,
anaesthesia and dose and duration of treatment. The type of
surgery may have a considerable effect on the incidence of
POCD, because cognitive impairments are more common after
cardiac surgery than after non-cardiac surgery [1]. Besides,
POCD is more common in major surgery than in minor surgery
[71]. Furthermore, even though all included studies measured
POCD in patients undergoing surgery under general
anaesthesia, the duration of surgery and the depth of
anaesthesia was variable. This is important to take into
account because Ballard et al. found that optimization of
anaesthetic depth led to a significant reduction in POCD at one
week post-surgery, with sustained benefits up to one year
post-surgery [72]. Furthermore, anaesthetics on their own may
have profound and long-lasting effects on the brain [73].
Finally, other individual factors such as attention deficits,
depression and alcohol and tobacco use also impact the
incidence of POCD [4].
Another limitation of the current study is the large dropout
of patients at follow-up. This dropout is likely confounded,
since patients who experience substantial decline are more
likely to be lost to follow-up. This may result in an
underestimation of the incidence of POCD. Finally, it is
important to note that the different agents that seem to
decrease the incidence of POCD are broadly active substances,
and it is unsure whether the beneficial effects are caused
exclusively by their anti-inflammatory actions.
Altogether, research into the use of different anti-
inflammatory agents to reduce POCD is still in its infancy. Only
few studies have been performed and many components with
strong anti-inflammatory potential, such as many NSAIDs,
specific antibiotics and corticosteroids, have not yet been
investigated. For future research into POCD, consistent
diagnostic criteria need to be developed along with a generally
accepted battery of neuropsychological tests to measure
POCD. Besides, decisions need to be made regarding the
optimal timing of measurement.
Conclusion
The current meta-analysis shows that anti-inflammatory
effects of agents may positively affect cognitive functioning
after surgery, as overall the administration of different anti-
inflammatory agents was found to significantly reduce the
incidence of POCD in patients. In addition to known-anti-
inflammatory drugs, many other substances with anti-
inflammatory properties were shown to improve POCD as well.
Although POCD as a surgical complication has only recently
been recognized, and a clear consensus about diagnostics is
not yet available, the present meta-analysis indicates that an
anti-inflammatory strategy may provide a promissing route to
proceed in the development of treatment for POCD. Further
research is necessary to determine which agents are most
appropriate for clinical application.
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